The key factors driving the growth of PDX Models Market include the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. The growing use of humanized PDX models is posing a lucrative opportunity in this market.
What the market looks like?
The PDX models market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at a CAGR of 16.7%.
Tumor Type:
The gastrointestinal tumors segment is expected to account for the largest share of the global PDX models market. The respiratory tumors segment, on the other hand, is expected to be the fastest-growing segment during the forecast period. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
Pre Clinical Drug Development and Basic Cancer Research:
The preclinical drug development and basic cancer research segment is expected to account for the largest share of the global PDX models market. The large share of this segment can be mainly attributed to the increasing number of research activities in the field of oncology drug research.
North America and Europe to Dominate The PDX Models Market:
North America accounted for the largest share of the PDx models market in 2017, followed by Europe. The large share of the North American PDX models market can be attributed to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to strong research expenditure and the well-structured CRO industry in China, growth in biomedical & medical research in Japan, rising pharmaceutical R&D expenditure in India, and rising translational and biomedical research in Singapore.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251
Key Players:
The key players in the PDX models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
PDX Models Market to Reflect Impressive Growth in Biomedical and Stem Cell Research
The report "HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification), Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021", Report provides a detailed overview of the major drivers, restraints, opportunities, trends, and strategies impacting the HIV diagnosis market along with the estimates and forecasts of the revenue and market share analysis.Browse 72 market data tables and 53 figures spread through 137 pages and in-depth TOC on "HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification), Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021"Get Free PDF - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66008285The HIV diagnosis market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021.
The major factors driving the growth of this market are increasing prevalence of HIV/AIDS worldwide, increasing number of blood transfusions and blood donations, advancements and benefits offered by point-of-care instruments & kits, and increasing awareness about HIV/AIDS and increasing government initiatives.The report segments this market based on product, test type, end user, and region.
On the basis of product, the market is segmented into consumables (assay, kits, reagents, and other consumables), instruments, and software and services.
In 2016, the consumables segment is expected to account for the largest share of the market.
The frequent and repetitive purchase of consumables by laboratories and hospitals, growing prevalence of HIV/AIDS, and increasing initiatives from governments to fight HIV/AIDS are some of the major factors driving the consumables market.On the basis of test type, the market is segmented into antibody tests, viral load tests, CD4 count tests, tests for early infant diagnosis, and tests for viral identification.
The antibody tests segment is further categorized into HIV-1 screening tests, HIV-1 confirmatory tests, and HIV-2 and group O diagnostic tests.
The report "HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification), Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021", Report provides a detailed overview of the major drivers, restraints, opportunities, trends, and strategies impacting the HIV diagnosis market along with the estimates and forecasts of the revenue and market share analysis.Browse 72 market data tables and 53 figures spread through 137 pages and in-depth TOC on "HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification), Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021"Get Free PDF - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66008285The HIV diagnosis market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021.
The major factors driving the growth of this market are increasing prevalence of HIV/AIDS worldwide, increasing number of blood transfusions and blood donations, advancements and benefits offered by point-of-care instruments & kits, and increasing awareness about HIV/AIDS and increasing government initiatives.The report segments this market based on product, test type, end user, and region.
On the basis of product, the market is segmented into consumables (assay, kits, reagents, and other consumables), instruments, and software and services.
In 2016, the consumables segment is expected to account for the largest share of the market.
The frequent and repetitive purchase of consumables by laboratories and hospitals, growing prevalence of HIV/AIDS, and increasing initiatives from governments to fight HIV/AIDS are some of the major factors driving the consumables market.On the basis of test type, the market is segmented into antibody tests, viral load tests, CD4 count tests, tests for early infant diagnosis, and tests for viral identification.
The antibody tests segment is further categorized into HIV-1 screening tests, HIV-1 confirmatory tests, and HIV-2 and group O diagnostic tests.